Grail, INC

GRAIL, Inc. announced first quarter 2026 financial results, showcasing significant year-over-year growth in revenue and test volume, alongside strategic advancements in healthcare integration.

GRAIL, Inc. announced its Q4 and full-year 2025 financial results, alongside topline data from the NHS-Galleri trial and PATHFINDER 2 study, highlighting significant commercial growth and progress in multi-cancer early detection.

GRAIL, Inc. presented preliminary financial results for 2025 and strategic updates at the J.P. Morgan Healthcare Conference, highlighting significant growth in Galleri test adoption and a strengthened cash position.

GRAIL, Inc. established an At-The-Market (ATM) equity offering program to sell up to $300 million of common stock and filed for the resale of 3.9 million shares.

GRAIL, Inc. reported strong third-quarter 2025 financial results with significant revenue growth and increased Galleri test volumes, alongside positive clinical data and strategic partnerships.

GRAIL, Inc. announced a $325.0 million private placement financing with institutional investors, significantly extending its operational funding into 2030.

GRAIL Inc. reported a 37% increase in screening revenue for Q1 2026, driven by higher Galleri test volumes, while net loss narrowed compared to the prior year.

GRAIL, Inc. reported reduced net losses in Q3 2025, driven by increased Galleri sales and cost optimization, while securing $435 million in new financing and presenting strong clinical trial data.

GRAIL, Inc. reports an 11% increase in total revenue for Q2 2025, driven by Galleri sales volume, while significantly narrowing net losses and continuing strategic restructuring efforts.

GRAIL Inc. reports a 24% increase in screening revenue for the first quarter of 2025, driven by higher Galleri test sales volume, while continuing to manage costs and pursue regulatory approval.

GRAIL, Inc. reports a net loss of $125.7 million for the third quarter of 2024, following its spin-off from Illumina and a restructuring plan.

GRAIL Inc. reported a significant net loss for the second quarter of 2024, driven by goodwill and intangible asset impairments, and announced a restructuring plan to focus on its core multi-cancer early detection business.

GRAIL reports increased Galleri sales and reduced net losses in 2025, but faces challenges with a missed primary endpoint in the NHS-Galleri Trial and ongoing regulatory hurdles for broad reimbursement.

GRAIL, Inc. aims to revolutionize early cancer detection with its Galleri test, targeting FDA approval in 2026 and expanding commercial partnerships.

William J Chase, a Director of GRAIL, Inc., received 276 shares of common stock on July 15, 2026.

Gregory L Summe, a Director of GRAIL, Inc., received 427 shares of common stock on July 15, 2026.

Steven Mizell, a Director of GRAIL, Inc., received 268 shares of common stock on July 15, 2026.

GRAIL, Inc. Chief Growth Officer Andrew Partridge sold 1,491 shares to cover tax obligations related to equity vesting.

GRAIL, Inc. CEO Joshua Ofman acquired 31,055 shares of common stock through restricted stock unit awards.

Director Steven Mizell acquired 396 shares of GRAIL, Inc. common stock through a deferred stock unit program.

GRAIL, Inc. is holding its 2026 Annual Meeting of Stockholders on June 18, 2026, and announced the planned retirement of CEO Robert Ragusa, with President Dr. Joshua Ofman set to take over as CEO.

GRAIL, INC. has filed a definitive proxy statement with the Securities and Exchange Commission.

GRAIL, INC. has filed a definitive proxy statement with the SEC.

GRAIL, Inc. reports strong growth for Galleri in 2024, progress in regulatory efforts, improved cost efficiency, and a new test version rollout, following its separation from Illumina.

Farallon Capital Management entities have reported beneficial ownership of over 5% of GRAIL, Inc. common stock, holding both shares and exercisable warrants.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in GRAIL Inc following an internal corporate realignment.

PRIMECAP Management Co./CA/ has filed an Amendment No. 2 to its Schedule 13G, reporting a beneficial ownership of 4.72% in GRAIL, Inc. as of December 31, 2025.

Farallon Capital and its affiliates filed an amended Schedule 13G, disclosing a 5.9% beneficial ownership in GRAIL, Inc. and reporting internal management changes.

Farallon Capital and its affiliates have disclosed a significant beneficial ownership stake of 5.5% in GRAIL, Inc. common stock.

Farallon Capital and its affiliates reported a beneficial ownership of less than 5% in GRAIL, Inc. as of November 4, 2025, following a brief period above the 5% threshold due to warrant acquisitions and subsequent sales.